Hematologia

Leucemias

Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Eduardo Guimarães	Iniciar	2008-005798-36

A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Manuel Sobrinho Simões	Iniciar	2015-001318-92

* Recrutamento ou Iniciar

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Eduardo Guimarães	Recrutamento	2014-001486-27

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Manuel Sobrinho Simões	Iniciar	2014-001617-12
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dr. António Almeida	Recrutamento	2014-001617-12

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dr. Jorge Coutinho	Recrutamento	2015-004856-24
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Ângelo Martins	Recrutamento	2015-004856-24

A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Sérgio Chacim	Recrutamento	2017-003540-21

A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Isabel Oliveira	Recrutamento	2018-001594-24

Mieloma Múltiplo

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Dra. Fernanda Trigo	Recrutamento	2014-001394-13
Hospital de Braga Lugar de Sete Fontes, S. Vitor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2014-001394-13
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Maria Manuela Bernardo	Recrutamento	2014-001394-13
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Nelson Domingues	Recrutamento	2014-001394-13
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Prof. Doutora Cristina João	Recrutamento	2014-001394-13

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital de Braga Lugar de Sete Fontes, S. Victor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2013-002076-41

Síndromes Mielodisplasicos

A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-Dependent Anemia And Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar Lisboa Central, E.P.E Alameda de Santo António dos Capuchos 1169-050 Lisboa - Portugal	Dra. Aida Botelho	Recrutamento	2012-002471-34
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Francesca Pierdomenico	Recrutamento	2012-002471-34

A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions.

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Márcio Tavares	Recrutamento	2017-003190-34

Linfomas

A Phase 4, Open–label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dr. Jorge Coutinho	Recrutamento	2012-004128-39
Hospital de Braga Rua das Sete Fontes 4710 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2012-004128-39
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Ana Espírito Santo	Recrutamento	2012-004128-39

Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with Previously Untreated Peripheral T-Cell Lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Maria Gomes da Silva	Recrutamento	2012-001580-68

Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Maria Gomes da Silva	Recrutamento	2012-002542-20

An open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera who are Hydroxyurea resistant or intolerant and for whom no treatment alternatives are available

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital de Braga Lugar de sete Fontes, S. Vitor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2014-001309-42

A randomised, open label, multi-centre, Phase III study to investigate the efficacy of bendamustine compared to treatment of physician's choice in the treatment of subjects with indolent Non-Hodgkin's Lymphoma (NHL) refractory to rituximab

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Dr. Fernando Principe	Recrutamento	2010-022102-41

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dr. Jorge Coutinho	Recrutamento	2015-001088-38
Hospital de Braga Lugar de Sete Fontes, S. Victor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2015-001088-38
Centro Hospitalar de Vila Nova de Gaia/Espinho Rua Conceição Fernandes, s/n 4434-502 Vila Nova de Gaia - Portugal	Dr. Henrique Coelho	Recrutamento	2015-001088-38
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino Almeida 4200-072 Porto - Portugal	Dra. Cláudia Moreira	Recrutamento	2015-001088-38

A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital de Braga Lugar de Sete Fontes, S. Victor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2014-005324-10

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dr. Jorge Coutinho	Recrutamento	2016-003202-14
Hospital CUF Descobertas Rua Mário Botas (Parque das Nações) 1998-018 Lisboa - Portugal	Dr. João Paulo Fernandes	Recrutamento	2016-003202-14
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino Almeida 4200-072 Porto - Portugal	Dr. José Mário Mariz	Recrutamento	2016-003202-14
Unidade Local de Saúde de Matosinhos Hospital Pedro Hispano Rua de Dr. Eduardo Torres Senhora da Hora - Portugal	Dr. Carlos Sottomayor	Recrutamento	2016-003202-14

A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dr. Jorge Coutinho	Recrutamento	2014-004689-11
Hospital de Braga Lugar de Sete Fontes, S. Victor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2014-004689-11
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Dulcineia Pereira	Recrutamento	2014-004689-11
Unidade Local de Saúde de Matosinhos Hospital Pedro Hispano Rua de Dr. Eduardo Torres Senhora da Hora - Portugal	Dr. Carlos Sottomayor	Recrutamneto	2014-004689-11

A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dr. Jorge Coutinho	Recrutamento	2013-003893-29
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Dra. Inês Carvalhais	Recrutamento	2013-003893-29
Centro Hospitalar de Vila Nova de Gaia/Espinho Rua Conceição Fernandes, s/n 4434-502 Vila Nova de Gaia - Portugal	Dr. Henrique Coelho	Recrutamento	2013-003893-29
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Sérgio Chacim	Recrutamento	2013-003893-29

* Recrutamento ou Iniciar

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Maria Gomes da Silva	Recrutamento	2013-000506-37

A phase 3, randomized, double-blind study of PF-05280586 versus rituximab for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital de Braga Lugar de Sete Fontes, S. Vitor 4710-243 Braga - Portugal	Dr. Herlander Marques	Recrutamento	2014-000132-41

A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Ilídia Moreira	Recrutamento	2018-002442-37